|
|
Post by sylvaing on Jan 26, 2017 15:43:58 GMT -5
We will know soon (March)
All the lagging that took place since Sanofi out...and Scripts at lowest levels!
I believe there is a plan and perhaps the RS was in the picture 2 years ago! but who knows....
We all know that one guy( Hakan Edstorm won't be on the payroll anymore in July because the TRANSITION will be complete (as mention in the communiqué December 2015)
What EXACTLY does mean TRANSITION.....we will know soon
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 26, 2017 15:48:24 GMT -5
We will know soon (March) All the lagging that took place since Sanofi out...and Scripts at lowest levels! I believe there is a plan and perhaps the RS was in the picture 2 years ago! but who knows.... We all know that one guy( Hakan Edstorm won't be on the payroll anymore in July because the TRANSITION will be complete (as mention in the communiqué December 2015) What EXACTLY does mean TRANSITION.....we will know soon There is no Transition. Its just a corporate way of saying things .He is an executive and he gets golden chute being good with Al . Al took care of him. He is on severance and his linked in profile states he is Retired ( assuming he personally updated his LinkedIn). |
|
|
|
Post by akemp3000 on Jan 26, 2017 16:14:14 GMT -5
No one has any idea what the real action plan is other than the few clues that have been provided: hiring direct sales force, TV commercials, international applications, insurance coverage progress, label change request and pediatric progress. All talk of RS thus far has been noise from message boards. There's been no clue or hint of a RS from management so let's hope there's more action plan news forthcoming.
|
|
|
|
Post by mnholdem on Jan 26, 2017 18:20:04 GMT -5
Our CEO will make MannKind Lean & Mean in 2017. I hear word that Matt even bought himself a new business suit:  |
|
|
|
Post by dreamboatcruise on Jan 26, 2017 18:23:20 GMT -5
No one has any idea what the real action plan is other than the few clues that have been provided: hiring direct sales force, TV commercials, international applications, insurance coverage progress, label change request and pediatric progress. All talk of RS thus far has been noise from message boards. There's been no clue or hint of a RS from management so let's hope there's more action plan news forthcoming. The things you list are exactly what they've listed as the plan... odd to say we have no idea and then list plan. As for RS... I think what Matt said on CC call certainly could be called a hint. He talked about it and stated it wasn't ruled out but that he hoped the balance sheet clean up and perhaps other things would push share price above a dollar. Contrary to his hope, the SNY settlement and balance sheet improvement did not create meaningful share price improvement. Seems from what has been said by management, would have to conclude that RS is at least under serious consideration. |
|
|
|
Post by sylvaing on Jan 26, 2017 20:58:32 GMT -5
Hi Dreamboatcruise,
Fully agree with you....the RS will be seriously considered now....and I believe this is what MNKD Management did plan 2 years ago.
They were asking too much for MNKD and knew that they were going to split from SNY partnership.
They were planning to go on their own since A. Mann knew that till sales were going to pick up.....no good offer were going to be on the table....
MNKD wanted to clean the Product monograph during the SNY partnership...which they did not finish enough rapidly
MNKD did 2 big mistakes....1. They should have raised money on FDA approval
2. They over estimated the sales potential of Afrezza by the word of mouth and electronic medias...
Now they are stuck with little cash and must extend till the PM is cleared....and I hope the pulmonary test is put as recommended but not an obligation
They did extend to max to get better insurance converage and get PM cleaned....they had few reps and they were only contractual selling other products...
in addition only few local advertising..... It is clear that all this was done on purpose.......scripts were supposed to go higher...but if SNY saw that they had a problem with renewall and retention of patients....MNKD knew also at that time.....only few patients had a success with low A1c....and it is good that MNKD concentrate on this...and titration...but this is all done at the expense of shareholders....
I do not believe that sales will pick up enough rapidly to avoid a RS unless MNKD get an extension from the NASDAQ...which I doubt if sales are not coming in.
It is obvious that the market does not want the SP to go up unless sales are there....so even if Management had good news...the share price will not go up since the Market does not want to see another financing......unless RS....
Hope I am wrong...and everthing will turn positive....
Cheers...
|
|
|
|
Post by matt on Jan 27, 2017 9:05:21 GMT -5
I do not believe that sales will pick up enough rapidly to avoid a RS unless MNKD get an extension from the NASDAQ...which I doubt if sales are not coming in. Even if MNKD gets an extension from NASDAQ, it will come with an obligation to execute a R/S. That is actually stated explicitly in the NASDAQ Marketplace Rules.
Any time something unpleasant is looming, like ripping off a Band-Aid, it is better to get it over with. Shareholders do not like reverse splits because the share price usually adjusts to the split ratio, which is just simple math, but then it is usually followed by a further substantial price decline but so is moving to the OTC market. Unpleasant as it may be, the only thing worse that doing a reverse split at this point is not doing a reverse split and losing the listing. Life is much better on NASDAQ which is why companies fight tooth and nail to stay listed. If script numbers are not improving enough to push the price over $1, it is best to get on with it.
|
|
|
|
Post by boca1girl on Jan 27, 2017 9:17:25 GMT -5
Hopefully we get positive news on Feb 01. Management will host an investor call after markets close.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2017 9:26:20 GMT -5
Castagna will also be on the call. Maybe his purpose is to reassure that the sales & marketing initiatives will move the needle or perhaps more than that. Has anyone ever heard of a company enduring a RS to go on to become successful? From what I know, RS merely extends the life of a terminally ill patient. Once a stock is delisted, what does it take to get it relisted on NASDAQ?
If we really started to see W/W NRx growth of 10% minimum and corresponding refill rates improving shortly thereafter, a three month extension without RS and I think SP would go over $1 in the March - May timeframe. Thoughts?
|
|
|
|
Post by kc on Jan 27, 2017 9:54:51 GMT -5
I wont get into the same long winded message that I have over the last 12 months. But the Board needs to put the company up for sale. We can't go it alone on a bootstrapped market plan. If you don't have the money to market and play the game you will ultimately fail. The board needs to find that buyer who has the capital to take it to the next level. The product is great but you can't sell something without a sales force and strong marketing/advertising.
Not sure what they are going to tell us on Wednesday but if it was good news it would occur pre-market and not at the market close.
|
|
|
|
Post by matt on Jan 27, 2017 13:41:38 GMT -5
Once a stock is delisted, what does it take to get it relisted on NASDAQ? If we really started to see W/W NRx growth of 10% minimum and corresponding refill rates improving shortly thereafter, a three month extension without RS and I think SP would go over $1 in the March - May timeframe. Thoughts? Once a stock is delisted, NASDAQ treats the company like any other which means the company is subject to all initial listing requirements which includes a $4 share price instead of $1, and shareholder equity of $4 million (versus MNKD's current equity that is at least two hundred million into negative territory). Thus to relist MNKD would have to raise a few hundred million in fresh capital and reverse split the shares anyway. It is far easier to stay listed than to relist.
As for your other question, it is debatable whether script growth alone would translate into a $1 share price. At that point it would all be market perception of whether such growth can continue. Three months at a compound weekly growth rate of 10% would only be 842 weekly scripts, and the weekly scripts needed to breakeven is in the tens of thousands. Would that be enough to convince the market that the tide has turned in MNKD's favor? Honestly, I don't know.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2017 13:44:25 GMT -5
stay tuned and tune into the call on Feb 1st
|
|
